We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Off-Label Drug Strategy Spells Trouble for Industry, Experts Say
Federal Off-Label Drug Strategy Spells Trouble for Industry, Experts Say
September 1, 2006
The government’s ability to wrest a $435 million settlement from a major drug company based on a single warning letter is a development that could signal significant future problems for the industry, a former FDA official says.